publication date: Nov. 3, 2017

Funding Opportunities The FY17 Defense Appropriations Act provides $10 million to the Department of Defense Kidney Cancer Research Program to support United States Army Medical Research Acquisition Activity 

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  

The managing agent for the anticipated program announcements/funding opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY17 KCRP program announcements and general application instructions for the following award mechanisms are posted on the Grants.gov website.

 

Consortium Development Award

Letter of Intent due December 20, 2017

An eligible principal investigator (who will be the consortium director) will be a faculty member at or above assistant professor (or equivalent) level.

Co-PIs should be at or above assistant professor (or equivalent) level.

Goal of the Consortium Development Award is to ensure the establishment of the consortium infrastructure for future multi-institutional clinical trials

Provides support to create a coordinating center and to establish the necessary collaborations at potential clinical trial sites for the development of a multi-institutional kidney clinical effort

Minimum of three separate institutes: one coordinating center and at least two clinical sites (other than … Continue reading The FY17 Defense Appropriations Act provides $10 million to the Department of Defense Kidney Cancer Research Program to support United States Army Medical Research Acquisition Activity

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.